Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, Other Mar 21 | 2023Senseonics Q4 ’22 Earnings and CGM Investor Event; OrsoBio Doses First Patient in Ph2 TLC-3595 Trial for Insulin ResistancePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Mar 17 | 2023Sanofi Follows Lilly and Novo's Insulin Price CutsPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 15 | 2023Nemaura Includes Insulin in EU DuoPack License Agreement; Sigilon Q4 ‘22 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Mar 14 | 2023Novo Nordisk to Lower US Insulin PricesPurchase Blast$599
Posted in: Other Mar 13 | 2023Sanofi Acquires Provention Bio; Ozempic Takes Stage at OscarsPurchase Blast
$599
Posted in: Dual/triple agonist, Other Mar 10 | 2023Mounjaro TV DTC Analysis; Intercept OCA Adcom SetPurchase Blast
$599
Posted in: Other Mar 09 | 2023Vertex Announces FDA Clearance of IND for VX-264 in T1DM; Akebia and Dario Q4 ’22 EarningsPurchase Blast
$599
Posted in: Glucagon, Other, SGLT2i Mar 08 | 2023FDA Accepts Jardiance Pediatric sNDA; New Teplizumab Pediatric Trial; Sernova Completes Islet Transplantation in First Two Ph1/2 T1DM Patients; Xeris and vTv Therapeutics Q4 ’22 EarningsPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Mar 06 | 2023CLEAR Outcomes Full Results; Abbott Libre 2 and 3 AID Clearance; New Lexicon HF Awareness Campaign; Merck to Advance Oral PCSK9i to Ph3; Amarin Announces Non-Sarissa Board Departures; BI/Lilly COORDINATE-Diabetes ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucagon, Glucose Monitoring, Other Mar 02 | 2023CMS Expands CGM Coverage; New Novo R&D Presence in Boston; Bigfoot Unity Android App Approval; Cytokinetic Receives Omecamtiv CRL; Galectin Finalizes Ph2b/3 NAVIGATE Randomization; Imcyse Completes Trial Enrollment; and Zealand, Intercept, and Amarin Q4 ’22 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Mar 02 | 2023US Insulin Pricing Analysis: Lilly cuts insulin prices by 70% and caps out-of-pocket costs at $35 per monthPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Feb 27 | 2023Esperion Launches Website Featuring CLEAR Outcomes; Abbott Receives 510(k) Approval for APIs; Novartis Initiates Ph3 Inclisiran Primary Prevention Trial; Nemaura and Viatris Q4 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring Feb 25 | 2023Dexcom’s Project Liberty Motives Are ConfusingPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 24 | 2023Insulet and MannKind Q4 ’22 Earnings; Novo Initiates Wegovy DTC; FDA Accepts G&L’s Bs-Glargine U100 BLA; Vadadustat Receives Positive CHMP Opinion; ATTD 2023 Key Press Releases Day 3Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 23 | 2023Apple Advances Non-Invasive Glucose Monitor; Tandem, Madrigal, Alnylam, and Teladoc Q4 ’22 Earnings; ATTD 2023 Key Press Releases Day 2Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Feb 22 | 2023Ionis Q4 ’22 Earnings; ATTD 2023 Key Press ReleasesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 21 | 2023Medtronic and Esperion CY Q4 ’22 Earnings Updates; Akebia Receives Another FDA Response for Vadadustat; Wegovy and Vadadustat CHMP Opinions; February CHMP AgendaPurchase Blast
$599
Posted in: DPP-IVi, Insulin Delivery Feb 17 | 2023Diabeloop Initiates DBL-4pen Trial; Glenmark’s Generic Onglyza Receives Tentative ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Feb 15 | 2023Biocon CY Q4 ’22 Earnings; Arrowhead Regains Rights to NASH Asset; Zydus Receives Tentative Approval for Generic InvokanaPurchase Blast